MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

Rhea-AI Summary

MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering platform technologies, will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes. The company invites investors to join a conference call at 4:30 p.m. Eastern Time, where management will discuss these results. Interested participants should register online in advance. A live and archived webcast of the call will be available on the MaxCyte website.

Positive

• Announcement of Q2 2024 financial results date.
• Management hosting a conference call for investors to discuss the results.

Negative

• None.

ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the second quarter 2024 after the U.S. market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation^® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

MaxCyte Contacts: 
US IR Adviser 
Gilmartin Group 
David Deuchler, CFA 
+1 415-937-5400 
ir@maxcyte.com  

US Media Relations 
Spectrum Seismic Collaborative 
Valerie Enes 
+1 408-497-8568 
venes@spectrumscience.com 

Nominated Adviser and Joint Corporate Broker 
Panmure Liberum
Emma Earl / Freddy Crossley 
Corporate Broking 
Rupert Dearden 
+44 (0)20 7886 2500 

UK IR Adviser 
ICR Consilium
Mary-Jane Elliott 
Chris Welsh 
+44 (0)203 709 5700
maxcyte@consilium-comms.com 

FAQ

When will MaxCyte announce its Q2 2024 financial results?

MaxCyte will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes.

What is the date and time for MaxCyte's Q2 2024 earnings conference call?

The Q2 2024 earnings conference call will be held on August 6, 2024, at 4:30 p.m. Eastern Time.

How can investors participate in MaxCyte's Q2 2024 earnings call?

Investors interested in MaxCyte's Q2 2024 earnings call need to register online in advance.

Where can I find the webcast for MaxCyte's Q2 2024 earnings call?

The live and archived webcast of MaxCyte's Q2 2024 earnings call will be available on the 'Events' section of the MaxCyte website.